NO20010956L - Modulering av hukommelseseffektor T-celler samt midler for dette - Google Patents

Modulering av hukommelseseffektor T-celler samt midler for dette

Info

Publication number
NO20010956L
NO20010956L NO20010956A NO20010956A NO20010956L NO 20010956 L NO20010956 L NO 20010956L NO 20010956 A NO20010956 A NO 20010956A NO 20010956 A NO20010956 A NO 20010956A NO 20010956 L NO20010956 L NO 20010956L
Authority
NO
Norway
Prior art keywords
cells
modulation
well
memory effector
effector
Prior art date
Application number
NO20010956A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010956D0 (no
Inventor
Daniel Magilavy
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO20010956D0 publication Critical patent/NO20010956D0/no
Publication of NO20010956L publication Critical patent/NO20010956L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20010956A 1998-08-31 2001-02-26 Modulering av hukommelseseffektor T-celler samt midler for dette NO20010956L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9845698P 1998-08-31 1998-08-31
PCT/US1999/020026 WO2000012113A2 (en) 1998-08-31 1999-08-31 Method of modulating memory effector t-cells using a cd2-binding agent, and compositions

Publications (2)

Publication Number Publication Date
NO20010956D0 NO20010956D0 (no) 2001-02-26
NO20010956L true NO20010956L (no) 2001-04-30

Family

ID=22269362

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010956A NO20010956L (no) 1998-08-31 2001-02-26 Modulering av hukommelseseffektor T-celler samt midler for dette

Country Status (26)

Country Link
US (2) US20020009446A1 (hu)
EP (1) EP1109570B1 (hu)
JP (1) JP2002523071A (hu)
KR (1) KR20010085687A (hu)
CN (1) CN100473417C (hu)
AT (1) ATE306932T1 (hu)
AU (1) AU764020B2 (hu)
BR (1) BR9913285A (hu)
CA (1) CA2339299C (hu)
CZ (1) CZ298238B6 (hu)
DE (1) DE69927831T2 (hu)
DK (1) DK1109570T3 (hu)
EA (1) EA005948B1 (hu)
EE (1) EE200100123A (hu)
ES (1) ES2252999T3 (hu)
HK (2) HK1038186A1 (hu)
HU (1) HUP0103563A3 (hu)
IL (2) IL141486A0 (hu)
IS (1) IS5848A (hu)
MX (1) MXPA01002111A (hu)
NO (1) NO20010956L (hu)
NZ (1) NZ510831A (hu)
PL (1) PL346339A1 (hu)
TR (1) TR200100607T2 (hu)
WO (1) WO2000012113A2 (hu)
ZA (1) ZA200101213B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
NZ510831A (en) * 1998-08-31 2002-12-20 Biogen Inc Method of modulating memory effector T-cells and compositions
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1409015A4 (en) * 2001-02-01 2006-04-12 Biogen Idec Inc METHODS OF TREATING OR PREVENTING SKIN DISORDERS USING CD2 BINDING AGENTS
EP1419236A4 (en) * 2001-07-24 2005-08-03 Biogen Idec Inc METHODS OF TREATING OR PREVENTING SCLEROSIS BY USE OF CD2-BINDING AGENTS
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
WO2005000898A2 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
WO2005035586A1 (ja) * 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
MXPA06008918A (es) * 2004-02-06 2007-03-07 Astellas Llc Metodos de tratamiento de trastornos de la piel.
US20080020383A1 (en) * 2004-05-04 2008-01-24 Genaissance Pharmaceuticals, Inc. Haplotype Markers And Methods Of Using The Same To Determine Response To Treatment
CA2565259A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
PL2021025T3 (pl) 2006-05-12 2017-04-28 Ith Immune Therapy Holdings Ab Sposób i środki do leczenia nieswoistego zapalenia jelit
CN101113459A (zh) * 2007-07-16 2008-01-30 东莞太力生物工程有限公司 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用
US8877177B2 (en) 2008-09-10 2014-11-04 Ith Immune Therapy Holdings Ab Chemokine containing apheresis column and methods of use
WO2014025198A2 (ko) * 2012-08-09 2014-02-13 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
WO2020236797A1 (en) * 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579844A (en) * 1976-05-13 1986-04-01 Johnson & Johnson Topical anti-inflammatory drug therapy
US4738927A (en) * 1982-03-31 1988-04-19 Ajinomoto Co. Inc. Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
JPH0763830B2 (ja) * 1985-11-26 1995-07-12 アスモ株式会社 ダイカスト鋳造金型への離型剤塗布方法
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5122514A (en) * 1990-04-23 1992-06-16 Abbott Laboratories Psoriasis treatment
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
PT503648E (pt) * 1991-03-12 2000-10-31 Biogen Inc Dominio do antigenio 3 associado a funcao linfocitica de ligacao as cd2
AU660312B2 (en) * 1991-06-06 1995-06-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same
US5511563A (en) * 1991-06-21 1996-04-30 Diamond; Donald A. Apparatus and method for treating rheumatoid and psoriatic arthritis
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DK0786255T3 (da) * 1991-10-07 2002-04-15 Biogen Inc Fremgangsmåde til forbedring af tolerancen for allotransplantater og xenotransplantater ved administration af et LFA-3- eller CD2-bindingsprotein
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
US5952499A (en) * 1995-01-16 1999-09-14 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound-fatty acid conjugates
NZ510831A (en) * 1998-08-31 2002-12-20 Biogen Inc Method of modulating memory effector T-cells and compositions
US6337337B1 (en) * 1998-09-03 2002-01-08 Carol J. Buck Methods for treating disorders responsive to DHFR-inhibition
EP1409015A4 (en) * 2001-02-01 2006-04-12 Biogen Idec Inc METHODS OF TREATING OR PREVENTING SKIN DISORDERS USING CD2 BINDING AGENTS
US20030068320A1 (en) * 2001-03-02 2003-04-10 Christine Dingivan Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders

Also Published As

Publication number Publication date
MXPA01002111A (es) 2003-03-27
IL141486A0 (en) 2002-03-10
HUP0103563A3 (en) 2004-04-28
ATE306932T1 (de) 2005-11-15
KR20010085687A (ko) 2001-09-07
EA005948B1 (ru) 2005-08-25
EE200100123A (et) 2002-06-17
TR200100607T2 (tr) 2001-06-21
DE69927831T2 (de) 2006-07-20
DK1109570T3 (da) 2006-03-06
AU764020B2 (en) 2003-08-07
IL141486A (en) 2007-12-03
WO2000012113A3 (en) 2000-06-29
CZ2001725A3 (cs) 2001-08-15
HK1040186A1 (zh) 2002-05-31
BR9913285A (pt) 2001-05-15
ZA200101213B (en) 2002-02-13
EP1109570B1 (en) 2005-10-19
DE69927831D1 (de) 2006-03-02
HUP0103563A2 (hu) 2002-01-28
CA2339299A1 (en) 2000-03-09
NZ510831A (en) 2002-12-20
CN100473417C (zh) 2009-04-01
ES2252999T3 (es) 2006-05-16
CN1315866A (zh) 2001-10-03
IS5848A (is) 2001-02-16
NO20010956D0 (no) 2001-02-26
US20020009446A1 (en) 2002-01-24
WO2000012113A2 (en) 2000-03-09
EP1109570A2 (en) 2001-06-27
US20060233796A1 (en) 2006-10-19
CZ298238B6 (cs) 2007-08-01
EA200100304A1 (ru) 2001-10-22
PL346339A1 (en) 2002-02-11
HK1038186A1 (en) 2002-03-08
JP2002523071A (ja) 2002-07-30
CA2339299C (en) 2009-02-10
AU6024499A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
NO20010956D0 (no) Modulering av hukommelseseffektor T-celler samt midler for dette
EA199800119A1 (ru) Ингибиторы адгезии клеток
BG101717A (en) Inhibitors of microsomal triglyceride transfer protein and method
ATE260910T1 (de) 4-heteroaryl-tetrahydrochinoline und ihre verwendung als inhibitoren des cholesterin-ester- transfer-proteins (ctep)
ITPN930026A0 (it) Sistema per la gestione di carichi elettrici domestici
ES2149888T3 (es) 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias.
DE69612003D1 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
ZA93811B (en) Methods of treating inflammatory dermatoses.
BG101966A (en) Application of 1l-agonist for the treatment of lack of urine retention
BG101326A (en) 6-aryl pyrido[2,3-d]pyrimidines and naphtharidines for cellular proliferation inhibition mediated from protein tyrosinekinase
ATE490311T1 (de) Mutanten der alpha-amylase
DE69928697D1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
IL138402A0 (en) Heterocyclically substituted amides used as calpain inhibitors
DK1053239T3 (da) Gluccocorticoid-selektive, anti-inflammatoriske midler
NO20004052L (no) Glukokortikoidselektive antiinflammatoriske midler
ES2139957T3 (es) Metodo para la determinacion del estado pretrombotico.
TR199902257T2 (xx) Tetrahidropirido bile�ikleri
DE69609864D1 (de) Steroidnitritesterderivate und ihre verwendung als entzündungshemmende medikamente
FR2691980B1 (fr) Procede de raffinage electrochimique direct de dechets de cuivre.
AU6000700A (en) Methods employing bacterial toxin-antitoxin systems for killing eukaryotic cells
AU2202301A (en) Cd45 inhibitors
NO954159D0 (no) Behandlede karbon- eller karbonbaserte katodiske komponenter for aluminiumproduksjonsceller
ATE209910T1 (de) Verwendung von 6,7-substituierter 2- aminotetraline zur behandlung von zytokin- vermittleten entzündungszuständen
TR199700146A2 (tr) Resikle polivinilklorürün rejenerasyonuna yönelik proses.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application